Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC4 | O15439 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.38 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.37 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2302711 | 1.00 | ABCC4 (0.63) | ABCC4MAPTALDH1A1LMNAMAOA | |
| SCHEMBL29915565 | 0.96 | ABCC4 (0.59) | ABCC4MAPTALDH1A1LMNAMAOA | |
| SCHEMBL16925547 | 0.94 | ABCC4 (0.59) | ABCC4MAPTALDH1A1LMNAMAOA | |
| SCHEMBL93540 | 0.85 | — | — | |
| SCHEMBL18045567 | 0.84 | MAOA (0.50) | ALDH1A1LMNAMAOAMAOBTSHR | |
| SCHEMBL18045569 | 0.84 | MAOA (0.50) | ALDH1A1LMNAMAOAMAOBTSHR | |
| SCHEMBL30972193 | 0.84 | ABCC4 (0.70) | ABCC4MAPTALDH1A1LMNATSHR | |
| SCHEMBL18045572 | 0.82 | MAOA (0.46) | ALDH1A1LMNAMAOAMAOBTSHR | |
| SCHEMBL1033281 | 0.80 | EPHX2 (0.42) | MAPTLMNAEPHX2 | |
| SCHEMBL4808838 | 0.80 | ABCC4 (0.44) | ABCC4MAPTALDH1A1LMNAMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 561 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11771657-B2 | Methods of delivering a neuroprotective polypeptide to the central nervous system | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-10-03 | — | — | US | claimed |
| US-20220265563-A1 | METHODS OF DELIVERING A NEUROPROTECTIVE POLYPEPTIDE TO THE CENTRAL NERVOUS SYSTEM | PEPTRON, INC. (KR) | 2022-08-25 | — | — | US | claimed |
| US-20200046645-A1 | METHODS OF DELIVERING A NEUROPROTECTIVE POLYPEPTIDE TO THE CENTRAL NERVOUS SYSTEM | PEPTRON, INC. (KR) | 2020-02-13 | — | — | US | claimed |
| EP-3528836-A1 | METHODS OF DELIVERING A NEUROPROTECTIVE POLYPEPTIDE TO THE CENTRAL NERVOUS SYSTEM | Peptron, Inc. (KR) | 2019-08-28 | — | — | EP | claimed |
| WO-2018075901-A9 | METHODS OF DELIVERING A NEUROPROTECTIVE POLYPEPTIDE TO THE CENTRAL NERVOUS SYSTEM | PEPTRON, INC. (KR) | 2018-06-07 | — | — | WO | claimed |
| WO-2018075901-A1 | METHODS OF DELIVERING A NEUROPROTECTIVE POLYPEPTIDE TO THE CENTRAL NERVOUS SYSTEM | PEPTRON, INC. (KR) | 2018-04-26 | — | — | WO | claimed |
| US-9155702-B2 | Composition and microsphere for controlled-release of exendin, and method preparing the same | PEPTRON CO., LTD (KR) | 2015-10-13 | — | — | US | claimed |
| US-20150080308-A1 | Formulations and Uses of Exendins and Exendin Agonist Analogs | AMYLIN PHARMACEUTICALS, LLC | 2015-03-19 | — | — | US | claimed |
| US-20150080307-A1 | EXENDINS AND EXENDIN AGONIST ANALOGS TO REGULATE GASTROINTESTINAL MOTILITY | AMYLIN PHARMACEUTICALS, LLC | 2015-03-19 | — | — | US | claimed |
| US-8951962-B2 | Modified exendins and exendin agonists | AMYLIN PHARMACEUTICALS, LLC (US) | 2015-02-10 | — | — | US | claimed |
| EP-1054594-A1 | INOTROPIC AND DIURETIC EFFECTS OF EXENDIN AND GLP-1 | AMYLIN PHARMACEUTICALS, INC. (US) | 2000-11-29 | — | — | EP | claimed |
| EP-1032587-A1 | NOVEL EXENDIN AGONIST COMPOUNDS | AMYLIN PHARMACEUTICALS, INC. (US) | 2000-09-06 | — | — | EP | claimed |
| EP-1019077-A1 | NOVEL EXENDIN AGONIST COMPOUNDS | AMYLIN PHARMACEUTICALS, INC. (US) | 2000-07-19 | — | — | EP | claimed |
| EP-0966297-A1 | METHODS FOR REGULATING GASTROINTESTINAL MOTILITY | AMYLIN PHARMACEUTICALS, INC. (US) | 1999-12-29 | — | — | EP | claimed |
| WO-1999040788-A1 | INOTROPIC AND DIURETIC EFFECTS OF EXENDIN AND GLP-1 | AMYLIN PHARMACEUTICALS, INC. (US) | 1999-08-19 | — | — | WO | claimed |
| WO-1999025728-A1 | NOVEL EXENDIN AGONIST COMPOUNDS | AMYLIN PHARMACEUTICALS, INC. (US) | 1999-05-27 | — | — | WO | claimed |
| WO-1999025727-A2 | NOVEL EXENDIN AGONIST COMPOUNDS | AMYLIN PHARMACEUTICALS, INC. (US) | 1999-05-27 | — | — | WO | claimed |
| WO-1999007404-A1 | NOVEL EXENDIN AGONIST COMPOUNDS | AMYLIN PHARMACEUTICALS, INC. (US) | 1999-02-18 | — | — | WO | claimed |
| WO-1998005351-A9 | METHODS FOR REGULATING GASTROINTESTINAL MOTILITY | — | 1998-05-28 | — | — | WO | claimed |
| WO-1998005351-A1 | METHODS FOR REGULATING GASTROINTESTINAL MOTILITY | AMYLIN PHARMACEUTICALS, INC. (US) | 1998-02-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220265563-A1 | METHODS OF DELIVERING A NEUROPROTECTIVE POLYPEPTIDE TO THE CENTRAL NERVOUS SYSTEM | GLP1R, IAPP, BDNF | ABCC4 479/4885MAPT 1643/4885ALDH1A1 4462/4885 |
| US-20200046645-A1 | METHODS OF DELIVERING A NEUROPROTECTIVE POLYPEPTIDE TO THE CENTRAL NERVOUS SYSTEM | GLP1R, IAPP, BDNF | ABCC4 479/4885MAPT 1643/4885ALDH1A1 4462/4885 |
| US-20150080308-A1 | Formulations and Uses of Exendins and Exendin Agonist Analogs | GLP1R, GCG, GCGR | ABCC4 2311/4885MAPT 3241/4885ALDH1A1 4830/4885 |
| US-11771657-B2 | Methods of delivering a neuroprotective polypeptide to the central nervous system | GLP1R, IAPP, BDNF | ABCC4 479/4885MAPT 1643/4885ALDH1A1 4462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.